In CD3xMock treated KPC3-TRP1 tumors, the observed effects were substantially less pronounced, with marginally increased necrotic tumor areas, CD8+ T cell numbers, and PD-L1 tumor cell expression only at 24 and 72 hours pi (online supplemental figure S5). Here, CD8A is linked to neoplasm.